neutral new phase mirasol set
start phase updat
messag report higher-than-consensu revenu opex
lower expect compani updat financi guidanc
expect end year w/ cash previous new
phase mirasol trial mirvetuximab ovarian cancer remain track start
year-end updat aml bpdcn monotherapi data
present oral guid previous updat estim reflect
report financi result updat financi guidanc revenu
primarili come non-cash royalti revenu kadcyla
higher consensu vs opex quarter lower
expect vs primarili due cost save result busi
restructur lower cost associ clinic develop fy revenu guidanc
increas due recognit defer revenu relat
collabor discontinu jun guidanc
opex lower year-end cash balanc
 compani end quarter
cash cash equival management continu guid cash runway
new phase mirasol trial mirvetuximab monotherapi ovarian cancer
track start year-end full trial result fail forward studi recent
present esmo confirm safeti profil mirvetuximab demonstr trend
improv orr os chemotherapi control fra-high patient
use altern biomark detect method score method exploratori
analysi differ mirvetuximab control appear enhanc mirasol
util score method evalu fr express level top-lin result
guid per manag trial higher power vs
mirvetuximab combin studi on-going combin regimen continu
evalu multi-cohort phase ii forward ii studi current focu
combin avastin platinum agnost ovarian cancer patient complet
enrol initi data combin avastin platinum-bas
chemotherapi platinum-sensit ovarian cancer patient updat data
updat phase data present recal initi
result form aml bpdcn patient dose-escal studi present
meet see note new cohort relaps acut lymphocyt
leukemia patient recent open addit two phase ii studi
one evalu monotherapi minim residu diseas posit mrd aml
patient follow frontlin induct therapi one studi vidaza
celg venclexta relapsed/refractori unfit aml patient recent
earli stage pipelin plan file ind adam
collabor moreov compani note next-gen
anti-fr enter pre-clinci develop
page analyst certif import disclosur
valuat risk
valu use discount cash flow analysi termin year post
assum mirvetuximab biosimilar entri use discount rate consist
develop stage biotech compani coverag termin growth rate
appli maintain neutral rate
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
pipelin success beyond alreadi account model
page analyst certif import disclosur
licens mileston fee
total cost expens
total expens incom
guggenheim secur llc estim sec file
page analyst certif import disclosur
licens mileston fee
total expens incom
net incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
